Amit Kumar Tiwari
Senior Patent Associate
Also affiliated: Jain University (2017); Birla Institute of Technology, Mesra (2021–2024); Government Medical College (2020); Motilal Nehru National Institute of Technology (2024); University of Allahabad (2024); Indian Veterinary Research Institute (2001–2022); Northern Alberta Institute of Technology (2025); Rani Durgavati University (2025); Symbiosis International University (2021–2025); Darbhanga Medical College and Hospital (2020–2021); Shyam Shah Medical College (2024); Diabetes Care and Research Foundation (2024); Institute of Post Graduate Medical Education and Research (2020); Era's Lucknow Medical College and Hospital (2020); Pacific Dental College and Hospital (2016); D.Y. Patil University (2024); Indian Agricultural Research Institute (2023); Bose (United States) (2020); Central University of Rajasthan (2013); Newcastle University (2015–2018); Vellore Institute of Technology University (2024); University of Toledo (2017); Gyan Vihar University (2025)
Faculty Researcher
COP | College of Pharmacy
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Dr. Amit Kumar Tiwari's research interests encompass medicinal chemistry, drug delivery systems, and the application of cheminformatics. He has investigated various therapeutic strategies, including the development of nanomedicines for cancer applications, such as resveratrol-loaded nanomedicines and pH-sensitive liposomes for enhanced drug delivery. His work also explores transdermal delivery systems for chemotherapeutics and the use of polyamide/poly(amino acid) polymers for drug delivery applications.
His academic background includes a Ph.D. in Chemistry with a specialization in Medicinal Chemistry, complemented by postgraduate diplomas in Cheminformatics and Patent Law. Dr. Tiwari is also certified in Intellectual Property Management by the World Intellectual Property Organization (WIPO) and holds certifications in competitive intelligence, acquisition, and mergers, as well as innovation management. He has published extensively, with a notable h-index of 12 and over 800 citations, indicating a significant impact in his fields of study. He maintains an active lab website and leads a research group, collaborating with colleagues at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 12
- Publications: 129
- Citations: 828
Selected Publications
-
Stability of Ketamine-Xylazine-Butorphanol formulation to establish an evidence-based beyond-use date (2026)
-
Targeting Microbiome-Derived Exosomes to Overcome Cancer Therapy Resistance: Mechanisms, Implications, and Opportunities (2025)
-
Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer (2025)
-
Dapagliflozin Reverses <scp>LPS</scp> ‐Induced Depressive–Like Behavior in Mice via Modulation of Glutamate and <scp>NF</scp> ‐ <scp>κB</scp> (2025)
-
An Update on Novel Drug Delivery Systems for the Management of Glaucoma (2025)
-
Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer (2025)
-
Endocytic highways: Navigating macropinocytosis and other endocytic routes for precision drug delivery (2025)
-
Strategies to Combat Resistance to Anti-angiogenesis Therapies in Cancer: Current Status and Future Prospects (2025)
-
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy (2025)
-
Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer (2024)
-
Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery (2024)
-
Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells (2024)
-
Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives (2024)
-
Review of Pharmacotherapeutic Targets in Alzheimer’s Disease and Its Management Using Traditional Medicinal Plants (2024)
-
Dietary Plant Metabolites Induced Epigenetic Modification as a NovelStrategy for the Management of Prostate Cancer (2024)
Research Interests
Dr. Tiwari is an Associate Dean of Research & Graduate Studies and a Professor of Pharmaceutical Sciences in the College of Pharmacy at University of Arkansas for Medical Sciences, Arkansas. He is a seasoned pharmacologist, a board-certified toxicologist and also leads a funded ?Cancer and Systems Therapeutics (CAST) program. He has been widely cited and has published, over 240 peer reviewed publications, patents and book chapters. CAST team is involved in a) developing effective, safe, and targeted anticancer molecules against multidrug-resistant cancers; b) designing, synthesizing and characterizing non-conventional forms of cell death inducers. CAST team has discovered first-in-class, safe agents that activate necroptosis, methuosis, methuophagy, ferroptosis, entosis, and immunogenic cell death, sensitizing resistant cancers to immuno- and radiotherapies. Integrating biomimetic microfluidics, high-content imaging, and AI-driven analytics, his group develops predictive tools to understand and overcome chemotherapy failure. In parallel, they are advancing patented macropinocytosis-based delivery platforms that enhance intracellular transport of siRNAs and proteins. Supported by multiple federal and foundation grants, issued patents, and international collaborations, Dr. Tiwari’s translational program bridges preclinical innovation with therapeutic impact.; Drug Discovery; Drug Resistance; Non Apoptotic Cell Death; Formulations, Drug; Drug Delivery Systems; Intellectual Properties
Grants & Funding
As listed on this researcher's institutional profile.
- Development of Novel Inducers of Non-Apoptotic Cell Death to Target TNBC US Department of Defense Principal Investigator
- High-throughput high-resolution microscopy for phenotypic drug discovery applications NIH/Nat. Inst. of Biomedical Imaging & Bioengineering via University of Toledo Principal Investigator
- ABI A. Tiwari Startup FY26 Y3 State of Arkansas Principal Investigator
Collaboration Network
Top Collaborators
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Dietary Plant Metabolites Induced Epigenetic Modification as a NovelStrategy for the Management of Prostate Cancer
- Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Showing 5 of 8 shared publications
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Dietary Plant Metabolites Induced Epigenetic Modification as a NovelStrategy for the Management of Prostate Cancer
- Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Showing 5 of 8 shared publications
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Dietary Plant Metabolites Induced Epigenetic Modification as a NovelStrategy for the Management of Prostate Cancer
- Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Showing 5 of 8 shared publications
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Dietary Plant Metabolites Induced Epigenetic Modification as a NovelStrategy for the Management of Prostate Cancer
- Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Showing 5 of 7 shared publications
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Dietary Plant Metabolites Induced Epigenetic Modification as a NovelStrategy for the Management of Prostate Cancer
- Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
- The Role of Cytokines in Activation of Tumour-promoting Pathways andEmergence of Cancer Drug Resistance
- Targeting Microbiome-Derived Exosomes to Overcome Cancer Therapy Resistance: Mechanisms, Implications, and Opportunities
- Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy
- Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery
- Rapidly Dissolving Trans-scleral Microneedles for Intraocular Delivery of Cyclosporine A
- Stability of Ketamine-Xylazine-Butorphanol formulation to establish an evidence-based beyond-use date
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Dietary Plant Metabolites Induced Epigenetic Modification as a NovelStrategy for the Management of Prostate Cancer
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- The Role of Cytokines in Activation of Tumour-promoting Pathways andEmergence of Cancer Drug Resistance
- Rapidly Dissolving Trans-scleral Microneedles for Intraocular Delivery of Cyclosporine A
- Stability of Ketamine-Xylazine-Butorphanol formulation to establish an evidence-based beyond-use date
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Strategies to Combat Resistance to Anti-angiogenesis Therapies in Cancer: Current Status and Future Prospects
- Targeting ferroptosis in gastric cancer: Strategies and opportunities
- Targeting ferroptosis in gastric cancer: Strategies and opportunities
- Targeting ferroptosis in gastric cancer: Strategies and opportunities
- Targeting ferroptosis in gastric cancer: Strategies and opportunities
Similar Researchers
Based on overlapping research topics